Miami, FL (January 28th, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of patients diagnosed with chronic obstructive pulmonary disease (COPD). [Read more…]
Applied StemCell Licenses Its TARGATT™ CHO Cell Technology for Biotherapeutics Development
Applied StemCell Licenses Its TARGATT™ CHO Cell Technology to Twist Bioscience Corp. for Biotherapeutics Development
Milpitas, California, January 19th, 2021 — The multi-platform gene-editing company, Applied StemCell (ASC), announced a commercial license of its TARGATT™ CHO technology to Twist Bioscience (Twist), a global innovative synthetic biology company. Execution of the license agreement was based on the evaluation result of the TARGATT™ CHO cell platform by Twist to assess its suitability for Twist’s antibody discovery, library screening, and bioproduction process. [Read more…]
Results from phase 3 gene therapy trial for painful diabetic peripheral neuropathy has been published online by Clinical and Translational Science
Results from the phase 3 gene therapy trial for painful diabetic peripheral neuropathy (DPN) have been published online by Clinical and Translational Science and suggest excellent safety profile and promising efficacy.
KEY POINTS
-
VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy.
Jellagen launches JellaGel™, the first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix
-
JellaGel™ uses Collagen Type 0 (marine sourced jellyfish) and is non-mammalian.
-
The hydrogel kit is easy to use (with Buffer and Crosslinker).
-
JellaGel™ can be used at room temperature.
Jellagen® Limited, a biotechnology company manufacturing high value Collagen Type 0 derived from jellyfish, announce the launch of their JellaGel™ Hydrogel. 3-dimensaional Hydrogels allow cells to grow and interact with all of their surroundings which makes a huge difference. [Read more…]
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
FLORHAM PARK, N.J. and NEW YORK, Jan. 8, 2021 — Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and GX Acquisition Corp. (Nasdaq: GXGX), a special purpose acquisition company, today announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity. Upon the closing of the transaction, which is expected to occur in the second quarter of 2021, GX Acquisition Corp. will be renamed Celularity Inc., and its common stock and warrants are expected to remain listed on Nasdaq under the new ticker symbols “CELU” and “CELUW.” [Read more…]
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 97
- Next Page »